1466 — Baijin Life Science Holdings Share Price
Last trade - 00:00- HK$525.23m
- HK$567.38m
- HK$53.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.06 | ||
| Price to Tang. Book | 16.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.61% | ||
| Return on Equity | -14.03% | ||
| Operating Margin | -5.91% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 111.98 | 43.32 | 62.65 | 86.88 | 53.68 | n/a | n/a | -20.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Baijin Life Science Holdings Ltd, formerly Affluent Partners Holdings Ltd, is an investment holding company principally engaged in the manufacture and sale of jewellery products. The Company operates the business through five segments. The Sales of Pearls and Jewellery Products segment is engaged in the design and sale of jewellery products as well as sale of pearls. The Brand marketing and Consulting Services segment is engaged in the provision of brand marketing and consulting services based on contracts with agreed terms of services. The Skincare Solutions Business segment is engaged in the sales of skincare solution products to cosmetic stores and hospitals by sales contracts as well as individuals via online sales platforms, under the brand name FO. The Research and Development Services segment is engaged in the Provision of professional scientific services. The Strategic Investment and Financial Services segment is engaged in the real estate financial assets investment.
Directors
- Chi Kin Cheng CHM (53)
- Sze Ming Cheung CFO (51)
- Tsz Hang Lee EDR (42)
- Alex Leung EDR (38)
- Mu Sheng Chen OTH (46)
- Lai Fong Cheung OTH (30)
- Wai Han Ma OTH (48)
- Kin Kwan Mok SEC (43)
- Sin Nang Chiu NID (60)
- Bo Dong NID (53)
- Siu Keung Wong NID (57)
- Last Annual
- March 31st, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- May 13th, 2014
- Public Since
- October 17th, 2014
- No. of Employees
- 84
- Sector
- Textiles & Apparel
- Industry
- Consumer Cyclicals
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 772,391,072
- Address
- Suites 2208-14, 22nd Floor, Sun Life Twr
- Web
- https://www.baijinlifescience.com/
- Phone
- +852 null36112188
- Auditors
- Moore Stephens CPA Limited
Latest News for 1466
Upcoming Events for 1466
Affluent Partners Holdings Ltd Annual Shareholders Meeting
Similar to 1466
361 Degrees International
Stock Exchange of Hong Kong Limited
Anta Sports Products
Stock Exchange of Hong Kong Limited
Asia Television Holdings
Stock Exchange of Hong Kong Limited
Best Pacific International Holdings
Stock Exchange of Hong Kong Limited
Billion Industrial Holdings
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:28 UTC, shares in Baijin Life Science Holdings are trading at HK$0.68. This share price information is delayed by 15 minutes.
Shares in Baijin Life Science Holdings last closed at HK$0.68 and the price had moved by +11.48% over the past 365 days. In terms of relative price strength the Baijin Life Science Holdings share price has outperformed the FTSE Developed Asia Pacific Index by +12.75% over the past year.
There is no consensus recommendation for this security.
Find out moreBaijin Life Science Holdings does not currently pay a dividend.
Baijin Life Science Holdings does not currently pay a dividend.
Baijin Life Science Holdings does not currently pay a dividend.
To buy shares in Baijin Life Science Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.68, shares in Baijin Life Science Holdings had a market capitalisation of HK$525.23m.
Here are the trading details for Baijin Life Science Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1466
Based on an overall assessment of its quality, value and momentum Baijin Life Science Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Baijin Life Science Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +44.11%.
As of the last closing price of HK$0.68, shares in Baijin Life Science Holdings were trading +21.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Baijin Life Science Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Baijin Life Science Holdings' management team is headed by:
- Chi Kin Cheng - CHM
- Sze Ming Cheung - CFO
- Tsz Hang Lee - EDR
- Alex Leung - EDR
- Mu Sheng Chen - OTH
- Lai Fong Cheung - OTH
- Wai Han Ma - OTH
- Kin Kwan Mok - SEC
- Sin Nang Chiu - NID
- Bo Dong - NID
- Siu Keung Wong - NID